Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD).’ The study aims to assess the efficacy of apremilast compared to a placebo in treating juvenile psoriatic arthritis in children aged 5 to under 18. This research is significant as it targets a pediatric population with limited treatment options.
The intervention being tested is Apremilast, an oral medication designed to treat active juvenile psoriatic arthritis. It is being compared to a placebo to evaluate its effectiveness and safety in the pediatric demographic.
The study follows an interventional design with randomized allocation and a parallel intervention model. Participants are masked in a quadruple manner, meaning the participant, care provider, investigator, and outcomes assessor are all unaware of the treatment assignments. The primary purpose of the study is treatment-focused.
Key dates for the study include its start date on March 16, 2021, and the most recent update on October 15, 2025. These dates are crucial as they indicate the timeline of the study’s progress and the latest developments.
The market implications of this study are significant for Amgen Inc., as positive results could enhance investor confidence and potentially boost the company’s stock performance. The study’s outcome could also influence the competitive landscape in the treatment of juvenile psoriatic arthritis, with Amgen potentially gaining a leading position.
The study is ongoing, and further details are available on the ClinicalTrials portal.